OTCMKTS:EVTCY Evotec (EVTCY) Stock Price, News & Analysis $1.60 -0.07 (-4.19%) As of 09/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC Filings About Evotec Stock (OTCMKTS:EVTCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evotec alerts:Sign Up Key Stats Today's Range$1.57▼$1.7550-Day Range$1.60▼$2.4352-Week Range$14.22▼$26.57Volume1.38 million shsAverage Volume2,407 shsMarket Capitalization$528.35 millionP/E Ratio3.90Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evotec SE is a Germany-based drug discovery and development company that partners with pharmaceutical, biotechnology and academic organizations. The company provides integrated research services and technology platforms designed to support the development of new medicines, from early-stage target identification and screening through preclinical research and selected clinical development activities. Evotec’s capabilities include small-molecule drug discovery, biologics research, cell and gene-related technologies, disease modeling, compound screening and data-driven drug development. Its scientific platforms include induced pluripotent stem cell research and targeted protein degradation, while its work spans therapeutic areas such as neuroscience, oncology, immunology, metabolic disease and infectious disease. Evotec also develops proprietary and partnered drug candidates, which may be advanced through collaborations with pharmaceutical companies and other research organizations. Founded in Hamburg in 1993 as Evotec BioSystems, the company has expanded its operations across Europe and the United States. Its activities are conducted through research and development sites in several locations, including Germany, the United Kingdom, France, Italy and the United States. Evotec is headquartered in Hamburg and is led by Chief Executive Officer Christian Wojczewski.AI Generated. May Contain Errors. Read More Receive EVTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVTCY Stock News HeadlinesEvotec, Plectonic Enter Research Collaboration For T-Cell-Engaging Solid Tumour TherapiesSeptember 2, 2026 | rttnews.comEvotec SE ADR (EVTCY)July 1, 2026 | nasdaq.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 21 at 1:00 AM | Weiss Ratings (Ad)Evotec SE: Evotec Receives Grants to Advance Tuberculosis TreatmentApril 30, 2026 | finanznachrichten.deEvotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related VirusesMarch 23, 2026 | finanznachrichten.deEvotec SE: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study InitiationMarch 19, 2026 | finanznachrichten.deEvotec SE: Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor RelationsJanuary 2, 2026 | finanznachrichten.deEvotec SE: Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation PartnershipNovember 12, 2025 | finanznachrichten.deSee More Headlines EVTCY Stock Analysis - Frequently Asked Questions How have EVTCY shares performed this year? Evotec's stock was trading at $3.08 at the beginning of the year. Since then, EVTCY shares have decreased by 48.1% and is now trading at $1.60. When did Evotec's stock split? Shares of Evotec split on Wednesday, October 20th 2021.The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were issued to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Evotec have any subsidiaries? Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others. How do I buy shares of Evotec? Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolOTCMKTS:EVTCY CIK1412558 Webwww.evotec.com Phone(494) 056-0810Fax49-40-5608-1222Employees4,200Year Founded1993Profitability EPS (Trailing Twelve Months)$0.41 Trailing P/E Ratio3.90 Forward P/E RatioN/A P/E GrowthN/ANet Income$7.14 million Net Margins20.85% Pretax Margin23.90% Return on Equity16.02% Return on Assets7.81% Debt Debt-to-Equity Ratio0.53 Current Ratio2.57 Quick Ratio2.50 Sales & Book Value Annual Sales$572.16 million Price / Sales0.92 Cash Flow$0.02 per share Price / Cash Flow105.53 Book Value$2.52 per share Price / Book0.63Miscellaneous Outstanding Shares330,221,000Free FloatN/AMarket Cap$528.35 million OptionableNot Optionable Beta0.98 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:EVTCY) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVTCY Stock Alerts